Insider Selling: uniQure (NASDAQ:QURE) CFO Sells 10,438 Shares of Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 10,438 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. The trade was a 4.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Christian Klemt also recently made the following trade(s):

• On Thursday, February 27th, Christian Klemt sold 2,916 shares of uniQure stock. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12.
• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The stock was sold at an average price of $7.55, for a total value of $13,559.80.

uniQure Trading Up 6.7 %

Shares of NASDAQ QURE traded up $0.76 during mid-day trading on Wednesday, hitting $12.09. 1,028,349 shares of the company traded hands, compared to its average volume of 1,042,863. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The stock has a market capitalization of $589.30 million, a price-to-earnings ratio of -2.44 and a beta of 0.38. The business has a 50 day moving average of $14.80 and a two-hundred day moving average of $9.89.

Institutional Investors Weigh In On uniQure

A number of large investors have recently made changes to their positions in the company. Twin Tree Management LP acquired a new position in uniQure in the 4th quarter worth approximately $77,000. FNY Investment Advisers LLC purchased a new position in shares of uniQure during the fourth quarter valued at $88,000. RTW Investments LP acquired a new position in uniQure during the third quarter valued at $49,000. ADAR1 Capital Management LLC purchased a new stake in uniQure in the 4th quarter worth about $177,000. Finally, Atria Investments Inc acquired a new stake in uniQure during the 3rd quarter worth about $53,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Cantor Fitzgerald boosted their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of uniQure in a research report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Guggenheim reiterated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, Mizuho boosted their target price on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.89.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.